6 CR, complete response; DOR, duration of response; MPT, - PowerPoint PPT Presentation

6 CR, complete response; DOR, duration of response; MPT, melphalan-prednisone-thalidomide; PR, partial response; Rd, lenalidomide and low-dose dexamethasone; Rd18, Rd for 18 cycles; VGPR, very good partial response. Bahlis N et al. Assessing the Benefit of Continuous Treatment in the FIRST Trial (MM-020): Impact of Response in Patients With Transplant-Ineligible Newly Diagnosed Multiple Myeloma. EHA 2015, abstract #P277.

8 2 × 2 DESIGN LEN + DEX × 4 INDUCTION MPR: 6 ASCT COURSES LEN: 2 COURSES NO NO LEN MNTC a LEN MNTC a LEN MNTC b PLACEBO PLACEBO LEN TREATMENT TREAT MNTC b (n = 229) (n = 231) (n = 307) (n = 307) (n = 67) (n = 68) MENT INTERIM ANALYSIS AND UNBLINDING DEC 2009 CONTINUED NO CROSSOVER TREATMENT CONTINUED CONTINUED CONTINUED CROSSOVER BEFORE PD TREATMENT TREATMENT TREATMENT ALL TREATMENT ALLOWED BEFORE PD ALLOWED DISCONTINUED Jan 2011

9 1.0 7-yr OS 0.8 Survival Probability 62% 0.6 50% 0.4 LENALIDOMIDE CONTROL 0.2 0.74 (0.62-0.89) .001 0.0 0 10 20 30 40 50 60 70 80 90 100 1 10 120 Overall Survival, mos Patients 605 578 555 509 474 431 385 282 200 95 20 1 0 at risk 604 569 542 505 458 425 350 271 174 71 10 0

• • • •

• • 

• • • • 